TipRanks
BridgeBio Oncology Therapeutics (BBOT)
NASDAQ:BBOT
US Market
BBOT
BridgeBio Oncology Therapeutics
RESEARCH TOOLSreports
Want to see BBOT full AI Analyst Report?

BridgeBio Oncology Therapeutics (BBOT) Stock Forecast & Price Target

76 Followers
See the Price Targets and Ratings of:

BBOT Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
BridgeBio
Oncology Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BBOT Stock 12 Month Forecast

Average Price Target

$19.63
▲(109.45% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for BridgeBio Oncology Therapeutics in the last 3 months. The average price target is $19.63 with a high forecast of $25.00 and a low forecast of $13.00. The average price target represents a 109.45% change from the last price of $9.37.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","8":"$8","14":"$14","20":"$20","26":"$26"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8,14,20,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.94,5.56,7.18,8.799999999999999,10.42,12.04,13.659999999999998,15.28,16.9,18.52,20.14,21.76,23.38,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.94,5.146538461538461,6.353076923076923,7.559615384615384,8.766153846153847,9.972692307692308,11.179230769230768,12.385769230769231,13.592307692307692,14.798846153846153,16.005384615384617,17.211923076923078,18.41846153846154,{"y":19.625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.94,4.636923076923077,5.333846153846154,6.030769230769231,6.727692307692308,7.424615384615384,8.121538461538462,8.81846153846154,9.515384615384615,10.212307692307693,10.909230769230769,11.606153846153846,12.303076923076924,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.21,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.52,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.03,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.08,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.03,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.39,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.09,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.82,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.94,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$25.00Average Price Target$19.63Lowest Price Target$13.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on BBOT
Sean Laaman
Morgan Stanley
Morgan Stanley
$13
Buy
38.74%
Upside
Reiterated
10/22/26
BridgeBio Oncology price target lowered to $13 from $18 at Morgan StanleyBridgeBio Oncology price target lowered to $13 from $18 at Morgan Stanley
Oppenheimer Analyst forecast on BBOT
Mazahir Alimohamed
Oppenheimer
Oppenheimer
$22→$16
Buy
70.76%
Upside
Reiterated
10/20/26
BridgeBio Oncology price target lowered to $16 from $22 at OppenheimerBridgeBio Oncology price target lowered to $16 from $22 at Oppenheimer
Leerink Partners Analyst forecast on BBOT
Andrew Berens
Leerink Partners
Leerink Partners
$27→$25
Buy
166.81%
Upside
Assigned
09/18/26
Analysts' Top Healthcare Picks: BridgeBio Oncology Therapeutics (BBOT), Entera Bio (ENTX)
J.P. Morgan Analyst forecast on BBOT
Priyanka Grover
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
09/15/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), Ascendis Pharma (NASDAQ: ASND) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)
Wedbush Analyst forecast on BBOT
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$25
Buy
166.81%
Upside
Reiterated
09/09/26
BridgeBio Oncology Therapeutics (BBOT) Receives a Buy from Wedbush
Stifel Nicolaus Analyst forecast on BBOT
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
$23→$15
Buy
60.09%
Upside
Reiterated
09/09/26
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR), Belite Bio, Inc. ADR (NASDAQ: BLTE) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)
Raymond James Analyst forecast on BBOT
Sean McCutcheon
Raymond James
Raymond James
$24→$22
Buy
134.79%
Upside
Reiterated
09/09/26
BridgeBio Oncology price target lowered to $22 from $24 at Raymond JamesBridgeBio Oncology price target lowered to $22 from $24 at Raymond James
Piper Sandler Analyst forecast on BBOT
Biren Amin
Piper Sandler
Piper Sandler
$21
Buy
124.12%
Upside
Reiterated
09/09/26
Analysts Offer Insights on Healthcare Companies: BridgeBio Oncology Therapeutics (NASDAQ: BBOT), Pharvaris (NASDAQ: PHVS) and Boston Scientific (NYSE: BSX)
Canaccord Genuity Analyst forecast on BBOT
John Newman
Canaccord Genuity
Canaccord Genuity
$23→$20
Buy
113.45%
Upside
Reiterated
09/09/26
BridgeBio Oncology price target lowered to $20 from $23 at CanaccordBridgeBio Oncology price target lowered to $20 from $23 at Canaccord
H.C. Wainwright Analyst forecast on BBOT
Robert Burns
H.C. Wainwright
H.C. Wainwright
$29
Buy
209.50%
Upside
Reiterated
05/01/26
Analyst Reiterates Buy on BridgeBio Oncology Therapeutics with Unchanged $29 12-Month Price Target Amid Promising Pan-KRAS Pipeline
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on BBOT
Sean Laaman
Morgan Stanley
Morgan Stanley
$13
Buy
38.74%
Upside
Reiterated
10/22/26
BridgeBio Oncology price target lowered to $13 from $18 at Morgan StanleyBridgeBio Oncology price target lowered to $13 from $18 at Morgan Stanley
Oppenheimer Analyst forecast on BBOT
Mazahir Alimohamed
Oppenheimer
Oppenheimer
$22→$16
Buy
70.76%
Upside
Reiterated
10/20/26
BridgeBio Oncology price target lowered to $16 from $22 at OppenheimerBridgeBio Oncology price target lowered to $16 from $22 at Oppenheimer
Leerink Partners Analyst forecast on BBOT
Andrew Berens
Leerink Partners
Leerink Partners
$27→$25
Buy
166.81%
Upside
Assigned
09/18/26
Analysts' Top Healthcare Picks: BridgeBio Oncology Therapeutics (BBOT), Entera Bio (ENTX)
J.P. Morgan Analyst forecast on BBOT
Priyanka Grover
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
09/15/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), Ascendis Pharma (NASDAQ: ASND) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)
Wedbush Analyst forecast on BBOT
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$25
Buy
166.81%
Upside
Reiterated
09/09/26
BridgeBio Oncology Therapeutics (BBOT) Receives a Buy from Wedbush
Stifel Nicolaus Analyst forecast on BBOT
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
$23→$15
Buy
60.09%
Upside
Reiterated
09/09/26
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR), Belite Bio, Inc. ADR (NASDAQ: BLTE) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)
Raymond James Analyst forecast on BBOT
Sean McCutcheon
Raymond James
Raymond James
$24→$22
Buy
134.79%
Upside
Reiterated
09/09/26
BridgeBio Oncology price target lowered to $22 from $24 at Raymond JamesBridgeBio Oncology price target lowered to $22 from $24 at Raymond James
Piper Sandler Analyst forecast on BBOT
Biren Amin
Piper Sandler
Piper Sandler
$21
Buy
124.12%
Upside
Reiterated
09/09/26
Analysts Offer Insights on Healthcare Companies: BridgeBio Oncology Therapeutics (NASDAQ: BBOT), Pharvaris (NASDAQ: PHVS) and Boston Scientific (NYSE: BSX)
Canaccord Genuity Analyst forecast on BBOT
John Newman
Canaccord Genuity
Canaccord Genuity
$23→$20
Buy
113.45%
Upside
Reiterated
09/09/26
BridgeBio Oncology price target lowered to $20 from $23 at CanaccordBridgeBio Oncology price target lowered to $20 from $23 at Canaccord
H.C. Wainwright Analyst forecast on BBOT
Robert Burns
H.C. Wainwright
H.C. Wainwright
$29
Buy
209.50%
Upside
Reiterated
05/01/26
Analyst Reiterates Buy on BridgeBio Oncology Therapeutics with Unchanged $29 12-Month Price Target Amid Promising Pan-KRAS Pipeline
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
SIBNSI-Bone
IMUXImmunic
MDWDMediwound
HROWHarrow Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BridgeBio Oncology Therapeutics

3 Months
David NierengartenWedbush
Success Rate
2/5 ratings generated profit
40%
Average Return
-6.10%
Copying David Nierengarten's trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -6.10% per trade.
1 Year
Sean LaamanMorgan Stanley
Success Rate
0/6 ratings generated profit
0%
Average Return
-62.17%
Copying Sean Laaman's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -62.17% per trade.
2 Years
Sean LaamanMorgan Stanley
Success Rate
0/6 ratings generated profit
0%
Average Return
-62.17%
Copying Sean Laaman's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -62.17% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BBOT Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
13
12
11
16
16
Buy
0
0
0
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
12
11
17
17
In the current month, BBOT has received 17 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BBOT average Analyst price target in the past 3 months is 19.63.
Each month's total comprises the sum of three months' worth of ratings.

BBOT Financial Forecast

BBOT Earnings Forecast

Next quarter’s earnings estimate for BBOT is -$0.69 with a range of -$0.80 to -$0.59. The previous quarter’s EPS was -$0.70. BBOT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BBOT has Performed in-line its overall industry.
Next quarter’s earnings estimate for BBOT is -$0.69 with a range of -$0.80 to -$0.59. The previous quarter’s EPS was -$0.70. BBOT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BBOT has Performed in-line its overall industry.
No data currently available

BBOT Sales Forecast

Next quarter’s sales forecast for BBOT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BBOT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BBOT has Performed in-line its overall industry.
Next quarter’s sales forecast for BBOT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BBOT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BBOT has Performed in-line its overall industry.

BBOT Stock Forecast FAQ

What is BBOT’s average 12-month price target, according to analysts?
Based on analyst ratings, BridgeBio Oncology Therapeutics’s 12-month average price target is 19.63.
    What is BBOT’s upside potential, based on the analysts’ average price target?
    BridgeBio Oncology Therapeutics has 109.45% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BBOT a Buy, Sell or Hold?
          BridgeBio Oncology Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is BridgeBio Oncology Therapeutics’s price target?
            The average price target for BridgeBio Oncology Therapeutics is 19.63. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $25.00 ,the lowest forecast is $13.00. The average price target represents 109.45% Increase from the current price of $9.37.
              What do analysts say about BridgeBio Oncology Therapeutics?
              BridgeBio Oncology Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of BBOT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.